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Abstract
Background: Approximately 20 % of all patients with colorectal cancer are diagnosed as having Stage IV cancer;
80 % of these present with unresectable metastatic lesions. It is controversial whether chemotherapy with or without
primary tumor resection (PTR) is effective for the treatment of patients with colorectal cancer with unresectable
metastasis. Primary tumor resection could prevent tumor-related complications such as intestinal obstruction,
perforation, bleeding, or fistula. Moreover, it may be associated with an increase in overall survival. However, surgery
delays the use of systemic chemotherapy and affects the systemic spread of malignancy.
Methods/design: Patients with colon and upper rectal cancer patients with asymptomatic, synchronous, unresectable
metastasis will be included after screening. They will be randomized and assigned to receive chemotherapy with
or without PTR. The primary endpoint measure is 2-year overall survival rate and the secondary endpoint measures are
primary tumor-related complications, quality of life, surgery-related morbidity and mortality, interventions with curative
intent, chemotherapy-related toxicity, and total cost until death or study closing day. The authors hypothesize that the
group receiving PTR following chemotherapy would show a 10 % improvement in 2-year overall survival, compared
with the group receiving chemotherapy alone. The accrual period is 3 years and the follow-up period is 2 years. Based
on the inequality design, a two-sided log-rank test with α-error of 0.05 and a power of 80 % was conducted. Allowing
for a drop-out rate of 10 %, 480 patients (240 per group) will need to be recruited. Patients will be followed up at every
3 months for 3 years and then every 6 months for 2 years after the last patient has been randomized.
Discussion: This randomized controlled trial aims to investigate whether PTR with chemotherapy shows better overall
survival than chemotherapy alone for patients with asymptomatic, synchronous unresectable metastasis. This trial
is expected to provide evidence so support clear treatment guidelines for patients with colorectal cancer with
asymptomatic, synchronous unresectable metastasis.
Trial registration: Clinicaltrials.gov NCT01978249.
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Background
Colorectal cancer is the third most common malignancy
in the world. About 940,000 cases of colorectal cancer
develop annually, and about 500,000 patients die annu-
ally [1]. Approximately 20 % of all patients with colorec-
tal cancer are diagnosed as having Stage IV cancer; 80 %
of these present with unresectable metastatic lesions [2].
The treatment of choice for colorectal cancer is radical
surgery, and additional chemotherapy or radiotherapy is
available to prevent residual microcarcinoma, distant
metastasis, and recurrence. However, in this incurable
situation, the treatment of choice is unclear. According
to the National Comprehensive Cancer Network guide-
lines [3], chemotherapy for colorectal cancer with unre-
sectable metastasis is recommended following palliative
resection of primary tumor only if the patient shows
tumor-related symptoms. When the patient has no tumor-
related symptoms, the first treatment option is chemother-
apy. Thereafter, surgery for the primary tumor and
metastatic lesions is recommended if the metastatic lesions
become resectable.
Primary tumor resection (PTR) requires time for the
patient to recover, which subsequently delays systemic
chemotherapy and affects the systemic spread of malig-
nancy. Several studies showed no significant difference
in overall survival rate between groups receiving PTR
and groups not receiving PTR [4, 5]. Moreover, since the
introduction of new chemotherapeutic agents and regi-
mens, several phase III trials have revealed prolonged
median overall survivals of 17–23 months for colorectal
cancer patients with distant metastases [6–8]. Thus,
some physicians prefer chemotherapy to PTR because of
these drawbacks of PTR and because of the low tumor-
related complication rates obtained with recently devel-
oped chemotherapeutic agents [4, 5, 9–11].
Conversely, many studies reported that PTR is necessary
in patients with unresectable distant metastases [12–19].
Primary tumor resection could prevent tumor-related
complications, such as intestinal obstruction, perforation,
bleeding, or fistula [15, 17]. These complications are asso-
ciated with poor oncologic outcomes as well as periopera-
tive morbidity and mortality. Moreover, recent papers
have reported significantly better overall survival rates for
patients undergoing PTR than patients who do not have
this treatment [12–14, 16, 18, 19]. We found similar re-
sults from data obtained at our institution [20]. Moreover,
National Comprehensive Cancer Network guidelines for
this issue are based on lower-level evidence (category 2A).
However, previous studies support each opposing con-
clusion, and these studies are all retrospective. Therefore,
we cannot know whether PTR should be performed or not
for the patients with unresectable distant metastasis. A
prospective, randomized controlled trial is required for this
reason. Thus, we have designed a clinical trial. The purpose
of this trial is to evaluate the role of PTR in colorectal can-
cer patients with asymptomatic, synchronous, unresectable
metastasis.
Methods/design
Objectives and endpoints
The authors will compare overall survival rates as the pri-
mary endpoint measure between a group undergoing PTR
followed by chemotherapy and a group undergoing only
chemotherapy. Primary tumor-related complication rates,
PTR-related complication rates, conversion rates to the
resectable state, total cost, and quality of life will be evalu-
ated as secondary endpoint measures. These evaluations
will allow us to know whether or not PTR has benefits
compared with the upfront chemotherapy strategy in
Stage IV colorectal cancer patients with asymptomatic,
synchronous, unresectable metastasis.
The primary endpoint measure is a comparison of 2-
year overall survival rates between both groups. Second-
ary endpoint measures are comparisons of quality of life,
total cost, and conversion to resectable status between
both groups. Moreover, primary tumor-related complica-
tion will be evaluated in the group receiving upfront
chemotherapy only and PTR-related morbidity and mortal-
ity will be evaluated in the group receiving PTR followed
by chemotherapy.
Definition and evaluation methods of parameters
Major primary tumor-related complications are intestinal
obstruction, lower gastrointestinal bleeding, perforation of
tumor, and fistula. Intestinal obstruction is defined from
such symptoms as abdominal discomfort, pain, nausea,
vomiting, abdominal distension or tenderness, rebound
tenderness on physical examination caused by primary
tumor, with evidence of obstruction shown in an abdom-
inal X-radiograph or computed tomograph. Lower gastro-
intestinal bleeding is defined as a bleeding from the
primary tumor, resulting in a reduction in hemoglobin
concentration, and requiring transfusion or intervention.
Tumor perforation includes both tumor perforation and
other site perforation owing to high pressure caused by pri-
mary tumor obstruction. Fistula is defined as fistula forma-
tion between the primary tumor and an adjacent organ, as
observed on physical examination or in imaging studies.
We consider the total cost to be all the colorectal
cancer-related cost. It is related not only with the treat-
ment itself, including surgery and chemotherapy, as well as
care during admission and in the outpatient department,
but also readmission due to adverse events or complica-
tions. In Korea, data on the cost of caring for Korean
patients can be obtained from the Ministry of Health and
Welfare, with approval.
To compare the quality of life between the two groups,
the Korean version of EQ-5DTM (EuroQol Group) and
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the European Organization for Research and Treatment
of Cancer Quality of Life Questionnaire-C30 will be
used. All the enrolled patients will complete the ques-
tionnaires before chemotherapy or PTR, and thereafter
every 6 months.
Morbidity and mortality related to PTR are graded
according to the Clavien–Dindo classification within
30 days after PTR [21], and chemotherapy-related toxicity
is evaluated by the National Cancer Institute Common
Terminology Criteria for Adverse Events, version 4.0 [22].
When the state of a tumor converts to resectable dur-
ing the trial, the treatment plan can be changed into
curative intent. Curative or radical resection is defined
as complete resection (R0) of both the primary tumor
and metastatic lesions, including radiofrequency ablation
for liver metastases.
Study design and period
This is a randomized, prospective, multicenter trial com-
paring chemotherapy following PTR with chemotherapy
alone in colorectal cancer patients with asymptomatic,
synchronous, unresectable metastases. The trial has been
registered at www.clinicaltrials.gov (NCT01978249).
All patients are randomized in a 1:1 ratio into one of two
arms after screening: chemotherapy only (control arm:
Arm 1) or chemotherapy after PTR (experimental arm:
Arm 2) (Fig. 1). The trial is expected to last 5 years. All eli-
gible patients will be enrolled after approval has been ob-
tained from the institutional review board at each
participating institution and enrollment will continue to
February 2017. Ethical approval has been received for the
trial from the following institutions: Severance Hospital
and Gangnam Severance Hospital, Yonsei University
College of Medicine, Kyungpook National University
Hospital, Soon Chun Hyang University Hospital, Ajou
University Hospital, Seoul National University Bundang
Hospital, Chonnam National University Hospital, Hallym
University Sacred Heart Hospital, National Cancer Center,
Yeungnam University Hospital. The accrual period is
3 years and the follow-up period is 2 years.
Details of treatment method in both comparative groups
Patients allocated to Arm 1 (chemotherapy only) will
receive chemotherapy first without PTR within 14 days
after randomization. They are divided into two chemo-
therapy groups: chemotherapy with or without target
agents. The chemotherapy regimens are outlined in Fig. 2.
The use of target agent (cetuximab, panitumumab, bev-
acizumab) is decided by the physician. This is one of
the stratification factors.
If it is decided that the patient will not receive target
agent, the first line of chemotherapy is 5-fluorouracil-
based combination therapy with irinotecan (FOLFIRI),
and the second line is 5-fluorouracil with oxaliplatin
(FOLFOX). If patients who received second-line therapy
need third-line therapy, they can be prescribed capecita-
bine or other chemotherapeutic agents or supportive care.
All chemotherapeutic agents will be used according to
the guidelines of the national health insurance service of
Korea. According to the results of K-ras mutation tests, an
appropriate target agent will be used. If the patient wants
to receive target agent, the first line of chemotherapy is
FOLFIRI with cetuximab or bevacizumab for patients
without the K-ras mutation and FOLFIRI with bevacizu-
mab for patients with the K-ras mutation. The second-line
therapy is xeloda with oxaliplatin (XELOX) or FOLFOX
with or without bevacizumab. The third-line therapy is
regorafenib, capecitabine, or supportive care.
Patients allocated to Arm 2 (chemotherapy after PTR)
will receive PTR within 14 days after randomization. Then
they will receive chemotherapy within 8 weeks after PTR.
The chemotherapy regimen is the same as that of Arm 1.
Fig. 1 Flow diagram of the trial. ASA, American Society of
Anesthesiologists; ECOG, Eastern Cooperative Oncology Group;
PTR, primary tumor resection
Fig. 2 Chemotherapy regimens. FOLFIRI, 5-fluorouracil-based
combination therapy with irinotecan; FOLFOX, 5-fluorouracil with
oxaliplatin; XELOX, xeloda with oxaliplatin
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Primary tumor resection is intended to obtain a
complete resection of the primary tumor (R0) with
negative resection margins and adequate lymphadenec-
tomy. The type of operation will be determined by the
location of the tumor, and may be right hemicolectomy,
transverse colectomy, left hemicolectomy, or anterior
resection. The surgeon can decide the method of oper-
ation, whether open or laparoscopic surgery. For the
primary site, a complete resection (R0) or microscopic
remnant resection (R1) should be confirmed by pathol-
ogists after PTR. Patients with visible incomplete resec-
tion (R2) are excluded from this study. Operative and
pathologic reports are documented in a case report
form. All adverse events occurring within 30 days after
PTR are recorded, using the Clavien–Dindo classifica-
tion of surgical complications [21].
Sample size calculation and randomization
The literature was searched to find a significant difference
in 2-year overall survival rates between Arms 1 and 2. Ruo
et al. [18] reported a 25 % probability of 2-year overall sur-
vival in resected patients compared with 6 % in patients
never resected (P < 0.001). Ferrand et al. [13] reported
similar results, of 24 % versus 10 % (P = 0.001). Galizia et
al. [14] reported a difference of 21 percentage points (38 %
versus 17 %). All the studies documented prolonged sur-
vival in the PTR group, as compared with the chemother-
apy only group. Thus, we hypothesized that Arm 2 would
show an improvement of 10 percentage points (approxi-
mately 47 % improvement) in 2-year overall survival rate
than Arm 1 (31 % versus 21 %). Considering the size of
each center, about 10,000 colorectal patients visit the trial
centers yearly. We assumed that 20 % of them would have
Stage IV cancer, and 80 % of these would have an unresect-
able metastasis. Finally, 10 % of patients would not present
with any symptom; therefore, approximately 160 patients
would be enrolled per year. The accrual period amounts to
3 years and the follow-up period amounts to 2 years. Based
on the inequality design, a two-sided log-rank test was con-
ducted, giving an α-error of 0.05 and a power of 80 %,
using PASS version 12 (NCSS statistical software, Kaysville,
UT, USA). The drop-out rate is expected to be 10 %; there-
fore, 480 patients (240 per group) must be enrolled.
Of the 480 subjects, 300 will be assigned to Arm 1 or
Arm 2 by permuted block randomization within strata
with block size 2 or 4. Randomization will be per-
formed in a 1:1 ratio, and stratified according to age
(<70 versus ≥70), Eastern Cooperative Oncology Group
performance status (0 versus 1 and 2), American
Society of Anesthesiologists score (1 and 2 versus 3),
and target agent (use versus no use). Because there will
not be so many enrolled patients in each center, owing to
the rarity of this kind of cancer, we will analyze data first
without considering the site effect, and then we will
analyze data considering the site effect as a random effect.
The remaining 180 subjects will be enrolled using the
Pocock and Simon minimization algorithm, to balance the
study groups [23]. Although the first 300 patients will be
randomized under the stratified randomization, the enroll-
ment speed will vary. This may result in an imbalance be-
tween the two groups, so we will use the minimization
method for later patients to balance the randomization
more precisely.
Enrollment criteria and detailed definitions
Inclusion criteria
1. Aged 20 years old or older
2. Histologically confirmed adenocarcinoma of the
colon or upper rectum
3. Resectable primary colon or upper rectal cancer and
unresectable metastatic lesions
4. No primary tumor-related symptoms
5. Eastern Cooperative Oncology Group performance
status of 0–2
6. Appropriate organ functions (hepatic transaminases
– less than five times the normal range; total
bilirubin – less than twice the normal range; serum
creatinine – less than 1.5 times the normal range;
platelets – more than 100,000/μl; neutrophil – more
than 1,500/μl)
7. American Society of Anesthesiologists score of ≤ 3
8. Able to give informed consent.
Exclusion criteria
1. The patient received adjuvant chemotherapy within
the past 6 months
2. The patient received chemotherapy for metastatic
colorectal cancer
3. The patient was planning to have curative surgery
for the metastatic lesions
4. The primary cancer is unresectable
5. Patients with peritoneal carcinomatosis
6. Patients with mid and low rectal cancer (≤10 cm)
7. Patients with primary tumor-related complications,
such as intestinal obstruction, intractable bleeding,
and perforation; these need to be treated
8. American Society of Anesthesiologists score of ≥ 4
9. The patient has chronic hepatitis or cirrhosis; an
asymptomatic carrier of hepatitis B virus or hepatitis
C virus may participate
10. Patients with an active infection, which requires
antibiotic therapy, during the randomization period
11. Pregnant or breastfeeding women
12. Patients who are enrolled in another clinical trial
during the time of enrollment (within the 28-day
randomization period)
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13. Patients who have had another different malignant
tumor in the previous 5 years; patients with treated
non-melanoma skin cancer or cervical cancer may
be enrolled.
‘Asymptomatic’ is defined as lack of primary-tumor-
related symptoms, including obstruction, lower gastrointes-
tinal bleeding, and perforation. Symptoms of obstruction
such as abdominal discomfort, pain, nausea, vomiting must
have not developed. There is no abdominal distension or
tenderness; rebound tenderness on physical examination
should be reported. No evidence of obstruction from ab-
dominal X-ray or computed tomography scan is required.
Bleeding from cancer, which results in a reduction in
hemoglobin concentration and requires transfusion or
intervention, is considered to be ‘symptomatic’. Patients
with non-specific symptoms, such as anorexia, dyspepsia,
general weakness, bowel habit change, or intermittent
hematochezia may be included in this trial.
‘Unresectable primary tumor’ is defined as a tumor in
which there is extensive involvement of the vena cava,
superior mesenteric artery, pancreas, and duodenum, as
observed in preoperative imaging study.
‘Unresectable metastasis’ is defined as follows:
1. After liver resection, the adjacent two segments of
liver cannot be preserved, or vascular inflow, outflow,
biliary drainage, and pedicle cannot be preserved, or
the remnant parenchyma of the liver is expected to be
less than 30 % of the total volume, or all the
metastatic lesions cannot be resected completely.
2. There are more than five metastatic lesions in the
lung parenchyma, or larger than lobectomy is
required, even if there are fewer than five metastatic
lesions, or the patient has insufficient respiratory
function (e.g., forced expiratory volume less than 1
liter per 1 second or less than 60 % of normal level).
3. The metastasis is discovered in the brain, bone,
neck, mediastinum, or retroperitoneal area.
Trial implementation
Informed consent will be obtained from all participants.
Patients who have agreed and signed an informed con-
sent form are randomized in a 1:1 ratio by stratification
after screening. The first visit is for screening. The par-
ticipant’s record includes name, screening number, birth
date, and date of signature, with the name of institution,
date of screening, and eligibility. After obtaining in-
formed consent from a potential patient, an investiga-
tor screens the patient with a screening number.
Randomization is performed using a computer-
generated random sequence. After randomization,
treatment begins within 2 weeks.
Evaluation items for screening are:
1. Past medical and surgical history
2. Physical examination
3. Eastern Cooperative Oncology Group performance
status
4. American Society of Anesthesiologists score
5. Electrocardiography
6. Complete differential blood count
7. Routine biochemical analysis, including glucose,
blood urea nitrogen, creatinine, electrolytes, total
protein, albumin, aspartate aminotransferase, alanine
aminotransferase, alkaline phosphatase, total bilirubin,
and uric acid
8. Tumor marker: carcinoembryonic antigen
9. Urine analysis
10. Colonoscopy and biopsy
11. Blood or urinary β-hCG (in a fertile woman)
12. Chest X-ray
13. Chest computed tomography (not mandatory if the
patient has undergone positron emission tomography)
14. Abdominal-pelvic computed tomography
15. Liver, brain, rectum magnetic resonance imaging,
bone scan, etc., for diagnosis of metastatic lesion
(if indicated)
16. Pulmonary function test for Arm 2 (PTR group) or
patient with lung metastasis.
Follow up
In Arm 1, chemotherapy must start within 2 weeks after
randomization. Follow-up appointments for study will
take place every 3 months for 3 years after the start of
chemotherapy, then every 6 months for 2 years. In Arm 2,
PTR must start within 2 weeks after randomization. The
next visit will be performed within 30 days after PTR, and
chemotherapy must start within 8 weeks after PTR.
Follow-up appointments for study are planned every
3 months for 3 years after starting day of chemotherapy,
then every 6 months for 2 years.
Data collection and management
We invited more than 20 centers having more than 500
beds and performing more than 100 surgeries for colo-
rectal cancer yearly in Korea; 16 of these centers agreed
to participate in the trial. Because the sites are located
far apart from each other, all clinical data and informa-
tion should be recorded and sent to our institution. We
will employ a web-based clinical research management
system (eVelos, provided by National Cancer Center,
Ilsan, Republic of Korea), which gathers clinical data and
information on-line. Principal investigators or clinical
research coordinators in each site should sign up to the
eVelos system and be trained in its use, and they will
enter clinical data onto an electronic case report form.
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Approved researchers in our institution will manage the
data and information (Fig. 3).
Dropping out
A participant can drop out of the study in the following
cases:
1. Unacceptable adverse events
2. An investigator stops for a participant’s benefit
3. Different treatment is required, which is not approved
in this trial
4. A participant refuses for any reason
5. A participant becomes pregnant, or discovers that
she is pregnant
6. Poor compliance
Statistical analysis
All patients who were allocated to either Arm 1 or Arm 2
by randomization will be included and their data will be
analyzed. Categorical and continuous data of the patients
for each intervention group will be analyzed. Two-year
overall survival rate, the primary endpoint measure of this
trial, will be estimated using Kaplan–Meier methods. In
addition, the hazard ratio will be compared by Stratified
Cox’s proportional hazards model. The assumption of
proportional hazards for the two study groups will be
checked by log-minus-log survival plots and the time-
dependent covariate test.
Secondary endpoint measures will be analyzed as fol-
lows: primary tumor-related complication will be evalu-
ated in the group receiving chemotherapy only and
PTR-related morbidity will be evaluated in the group
receiving PTR followed by chemotherapy. The quality of
life, as assessed using the aforementioned question-
naires, will be compared between both arms using a lin-
ear mixed model. The total cost until closure of trial will
be compared using a t test in both arms. Significance
will be considered for P less than 0.05. All analyses will
be performed using SPSS version 20.0 (SPSS Inc., IBM
Corp., Armonk, NY, USA), SAS (version 9.2, SAS Inc.,
Cary, NC, USA), and R package, version 3.0.3 (https://
www.R-project.org).
Safe evaluation and reporting of adverse effect
Adverse events and serious adverse events must be re-
ported to protect participants. Complications, including
surgery-related morbidity, primary tumor-related com-
plications, and chemotherapy-related toxicity, should be
recorded in the electronic case report form. Serious
adverse events should be reported every 3 months;
suspected, unexpected, serious, adverse reactions, which
could result in death or are life threatening, should be
reported within 15 days of detection by investigators.
Data monitoring
A committee will be organized for trial supervision. All
members of the committee are certified according to the
course of good clinical practice in each institution. All
process including data collection, records, and manage-
ment will be monitored by them. The committee will
check the interim results at least yearly, and they can
advise and consult the principal investigator. Interim
results will also be reported to the Ministry of Health
and Welfare yearly for the overall trial period. If the
Fig. 3 Data collection and management
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interim results are considered not to sustain the trial
(i.e., significant better or worse treatment arm, excessive
morbidity), the chief of the Ministry of Health and
Welfare can decide to withdraw an institution or cancel
the entire trial.
Ethical and legal considerations
The authors follow the Declaration of Helsinki to pro-
tect the patients, and the trial will be performed accord-
ing to the guidelines of the International Council for
Harmonization – Good Clinical Practice. Each institu-
tion that participates in this trial must obtain approval
from its own institutional review board. All patients will
understand and agree to the aims and process of the
trial, and the possible results and risks. An informed
consent form must be written in language that the
patients can understand, and must be explained by an
investigator. If patients cannot read an informed consent
form, an investigator must read it in the presence of a
witness. Although a patient has signed an informed con-
sent form at first, an investigator must cancel the
process if the patient subsequently refuses. A copy of the
signed informed consent form should be provided to the
patient. An original copy will be held in an investigator’s
safe keeping.
Medical records of the patients can be reviewed for
the aims of the trial only by strictly authorized persons.
Randomization number and initials of patients are
recorded in the case report form, but not other data,
such as full name or registration number.
Discussion
Between PTR with chemotherapy and chemotherapy
only, which is better has remained unclear and contro-
versial for the treatment of asymptomatic colorectal can-
cer patients with unresectable metastasis considering
oncologic outcomes. Moreover, in terms of complica-
tions, Poultsides et al. [11] reported that 11 % of 233
patients with synchronous Stage IV colorectal cancer
developed primary tumor-related complications and only
7 % required emergent surgery. In their study, seven pa-
tients underwent intraluminal stenting successfully.
Eventually, Poultsides et al. [11] concluded that their
data supported the use of chemotherapy without routine
prophylactic resection, as the appropriate standard
practice for patients with neither obstructing nor hemor-
rhaging primary colorectal tumors in the setting of
metastatic disease. Meanwhile, in our data, primary
tumor-related complication rates of 252 patients in our
institution were 35 %, and 8 % required emergent surgery
[20]. Moreover, Van Hooft et al. [24] closed their multi-
center randomized clinical trial comparing endoscopic
stenting versus surgery for Stage IV left-sided colorectal
cancer because of high numbers of complications (i.e., 6
perforations of 11 patients who underwent stent
insertion). They reported that the safety of non-operative
intervention instead of PTR was questionable.
Postoperative mortality rates following palliative resec-
tion were reported to be 8.3–9.8 % by publications be-
fore 2000 [17, 25, 26]. However, these rates have
decreased to 0–5 % since 2000 [12, 14, 18]. This de-
crease would be because of development of operative
technique, anesthesiology, and postoperative manage-
ment. According to data from our institution, the 30-day
mortality rate after PTR was 1.9 % [20]. These results
favor PTR.
However, all these retrospective studies cannot be used
to establish treatment guideline because of their inherent
bias. Thus, this trial is proposed and aims to provide
critical data, to support the establishment of a standard
treatment protocol for patients with asymptomatic Stage
IV colorectal cancer with unresectable metastasis. In this
clinical trial, quality of life is secondary endpoint meas-
ure. If this clinical trial finds any differences of quality of
life between two treatment groups, this will be invalu-
able knowledge for the patients even if oncologic out-
comes are similar between treatment methods. Another
secondary endpoint measurement is comparison of
hospital cost between the two treatment methods. This
comparison will provide important knowledge not only
for patients but also for government health policy
makers, who want to establish a cost-effective medical
system.
The trial started with the first enrolled patient in
October 2013. The authors expect that this trial will find
an optimal treatment strategy for asymptomatic colorec-
tal cancer patients with unresectable metastasis with
level 1 evidence.
Trial status
This study is currently in the recruitment phase.
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